Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREATH: PT027 for Exercise-Induced Bronchoconstriction
NCT06245551Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2023
- Primary completion
- Jun 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of salbutamol + budesonide in asthma and Exercise-induced bronchoconstriction (EIB) (2 arms), sponsored by AstraZeneca. Primary endpoint: Maximum Percentage Fall From Post-dose, Pre-exercise Baseline in Forced Expiratory Volume in 1 Second. Started Dec 2023; status: completed.
02
Drugs
salbutamol + budesonide
03
Conditions
asthmaExercise-induced bronchoconstriction (EIB)
Beyond the preview
Go deeper on NCT06245551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06245551.